353 related articles for article (PubMed ID: 9331099)
21. c-erbB-2 amplification in node-negative human breast cancer.
Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
[TBL] [Abstract][Full Text] [Related]
22. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
23. [Amplification and overexpression of c-erbB2 in human breast cancer].
Chen Y; Dong J; Li C
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):16-9. PubMed ID: 7656779
[TBL] [Abstract][Full Text] [Related]
24. Replication error in human breast cancer: comparison with clinical variables and family history of cancer.
Huiping C; Johannsdottir JT; Arason A; Olafsdottir GH; Eiriksdottir G; Egilsson V; Ingvarsson S
Oncol Rep; 1999; 6(1):117-22. PubMed ID: 9864413
[TBL] [Abstract][Full Text] [Related]
25. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
[TBL] [Abstract][Full Text] [Related]
26. c-myc amplifications in primary breast carcinomas and their local recurrences.
Aulmann S; Adler N; Rom J; Helmchen B; Schirmacher P; Sinn HP
J Clin Pathol; 2006 Apr; 59(4):424-8. PubMed ID: 16497871
[TBL] [Abstract][Full Text] [Related]
27. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
28. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.
Cuny M; Simony-Lafontaine J; Rouanet P; Grenier J; Valles H; Lavaill R; Louason G; Causse A; Lequeux N; Thierry C
Oncol Res; 1994; 6(4-5):169-76. PubMed ID: 7841539
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.
Shen CY; Yu JC; Lo YL; Kuo CH; Yue CT; Jou YS; Huang CS; Lung JC; Wu CW
Cancer Res; 2000 Jul; 60(14):3884-92. PubMed ID: 10919664
[TBL] [Abstract][Full Text] [Related]
30. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer.
Tanner MM; Tirkkonen M; Kallioniemi A; Isola J; Kuukasjärvi T; Collins C; Kowbel D; Guan XY; Trent J; Gray JW; Meltzer P; Kallioniemi OP
Cancer Res; 1996 Aug; 56(15):3441-5. PubMed ID: 8758909
[TBL] [Abstract][Full Text] [Related]
31. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
Rodríguez-Pinilla SM; Rodríguez-Gil Y; Moreno-Bueno G; Sarrió D; Martín-Guijarro Mdel C; Hernandez L; Palacios J
Am J Surg Pathol; 2007 Apr; 31(4):501-8. PubMed ID: 17414096
[TBL] [Abstract][Full Text] [Related]
32. Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors.
Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Koutroumbi E; Markopoulos C; Gogas J; Kittas C
Anticancer Res; 2001; 21(2A):991-9. PubMed ID: 11396193
[TBL] [Abstract][Full Text] [Related]
33. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread.
Tsuda H; Callen DF; Fukutomi T; Nakamura Y; Hirohashi S
Cancer Res; 1994 Jan; 54(2):513-7. PubMed ID: 8275489
[TBL] [Abstract][Full Text] [Related]
34. HER2 genetic heterogeneity in breast carcinoma.
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
J Clin Pathol; 2011 Dec; 64(12):1112-6. PubMed ID: 22011446
[TBL] [Abstract][Full Text] [Related]
35. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.
Kauraniemi P; Bärlund M; Monni O; Kallioniemi A
Cancer Res; 2001 Nov; 61(22):8235-40. PubMed ID: 11719455
[TBL] [Abstract][Full Text] [Related]
36. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
37. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
38. Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event.
Paterson AL; Pole JC; Blood KA; Garcia MJ; Cooke SL; Teschendorff AE; Wang Y; Chin SF; Ylstra B; Caldas C; Edwards PA
Genes Chromosomes Cancer; 2007 May; 46(5):427-39. PubMed ID: 17285574
[TBL] [Abstract][Full Text] [Related]
39. Amplification, expression, and steroid regulation of the preprogalanin gene in human breast cancer.
Ormandy CJ; Lee CS; Ormandy HF; Fantl V; Shine J; Peters G; Sutherland RL
Cancer Res; 1998 Apr; 58(7):1353-7. PubMed ID: 9537228
[TBL] [Abstract][Full Text] [Related]
40. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer.
Caldés T; Perez-Segura P; Tosar A; de La Hoya M; Diaz-Rubio E
Teratog Carcinog Mutagen; 2000; 20(5):283-91. PubMed ID: 10992275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
